Received Jun 15, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | PS4D9 | — |
Prefilled syringe administered 5 days after activation; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong technique in product usage process in a 22-year-old female patient who received DTPa (Reduced antigen) (Boostrix) suspension for injection in pre-filled syringe (batch number PS4D9 with expiry date 19-JUN-2028) for prophylaxis. On 26-MAY-2026, the patient received Boostrix. On 26-MAY-2026, an unknown time after receiving Boostrix, the patient experienced wrong technique in product usage process (Verbatim: Prefilled syringe administered 5 days after activation). The outcome of the wrong technique in product usage process was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 11-JUN-2026 Clinic administrator mentioned that on 21-MAY-2026 they activated a prefilled syringe of Boostrix, but they ended up not giving it, so it was stored in the fridge, and on 26-MAY-2026 that vaccine was finally administered to a patient.